Live Breaking News & Updates on Differentiated Thyroid

Stay updated with breaking news from Differentiated thyroid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer | Small Molecules

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer | Small Molecules
pipelinereview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pipelinereview.com Daily Mail and Mail on Sunday newspapers.

United States , Marcias Brose , Drug Administration , Takeda Pharmaceutical Company , American Thyroid Association , Iexelixis Inc , Exelixis Inc , European Thyroid Association Guidelines For The Treatment , Community Based Clinical Trials , European Union , American Cancer Society , Prescription Drug User Fee Act , United Statesi September , Breakthrough Therapy , Priority Review , Jefferson Torresdale Hospital , Sidney Kimmel Cancer Center , Thomas Jefferson University , Takeda Pharmaceutical Company Limited , Growing Companies , Guidelines Taskforce , Thyroid Nodules , Differentiated Thyroid , Thyroid Association Guidelines , Advanced Radioiodine Refractory Thyroid , Eur Thyroid ,

Exelixis Announces Cabozantinib Significantly Improved Progression-Free Survival in COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer

Published: Dec 21, 2020
ALAMEDA, Calif. (BUSINESS WIRE) Exelixis, Inc. (NASDAQ: EXEL) today announced that COSMIC-311, the phase 3 pivotal trial evaluating cabozantinib (CABOMETYX
®) versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after up to two prior vascular endothelial growth factor receptor (VEGFR)-targeted therapies, met the co-primary endpoint of demonstrating significant improvement in progression-free survival. Cabozantinib reduced the risk of disease progression or death by 78% with a hazard ratio of 0.22 (96% CI 0.13 – 0.36; p ....

United States , Marcias Brose , Gisela Schwab , Abramson Cancer Center , Takeda Pharmaceutical Company , American Thyroid Association , Exchange Commission , Product Development , Exelixis Inc , European Union , University Of Pennsylvania , American Cancer Society , Full Professor , Neck Surgery , Rare Cancers , Personalized Therapy , Medical Affairs , Chief Medical Officer , Takeda Pharmaceutical Company Limited , Hypertensive Crisis , Plantar Erythrodysesthesia , Impaired Wound Healing , Posterior Leukoencephalopathy Syndrome , Fetal Toxicity , Prescribing Information , Growing Companies ,